• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

评估挽救性化疗治疗复发/难治侵袭性淋巴瘤相关的间接医疗成本：加拿大癌症临床试验组（CCTG）LY.12 临床试验的亚组分析。

Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial.

机构信息

Canadian Cancer Trials Group, Queen's University, Kingston, ON K7L 3N6, Canada.

出版信息

Curr Oncol. 2021 Mar 17;28(2):1256-1261. doi: 10.3390/curroncol28020119.

DOI:10.3390/curroncol28020119
PMID:33802634
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8025821/
Abstract

We conducted an analysis of indirect costs alongside the LY.12 randomized trial in patients with relapsed or refractory (R/R) aggressive non-Hodgkin lymphoma (NHL). Lost productivity data for Canadian patients and caregivers in the trial were collected at baseline and with each chemotherapy cycle pre-transplant, using an adapted Lost Productivity questionnaire. Mean per patient indirect costs were CAD 2999 for patients in the GDP arm and CAD 3400 in the DHAP arm. A substantial majority was not working or had to reduce their workload during this treatment time. Salvage chemotherapy for R/R aggressive NHL is associated with significant indirect costs to patients and their caregivers.

摘要

我们在 LY.12 随机试验中对复发或难治性（R/R）侵袭性非霍奇金淋巴瘤（NHL）患者的间接成本进行了分析。使用改良后的生产力损失问卷，在试验中收集了加拿大患者和护理人员在基线和每次移植前化疗周期的生产力损失数据。GDP 组每位患者的平均间接成本为 2999 加元，DHAP 组为 3400 加元。绝大多数患者在治疗期间无法工作或不得不减少工作量。挽救性化疗治疗 R/R 侵袭性 NHL 会给患者及其护理人员带来巨大的间接成本。

相似文献

1
Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial.评估挽救性化疗治疗复发/难治侵袭性淋巴瘤相关的间接医疗成本：加拿大癌症临床试验组（CCTG）LY.12 临床试验的亚组分析。
Curr Oncol. 2021 Mar 17;28(2):1256-1261. doi: 10.3390/curroncol28020119.
2
Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12.吉西他滨/地塞米松/顺铂与阿糖胞苷/地塞米松/顺铂治疗复发或难治性侵袭性组织学淋巴瘤：NCIC CTG LY.12 的成本效用分析。
J Natl Cancer Inst. 2015 Apr 13;107(7). doi: 10.1093/jnci/djv106. Print 2015 Jul.
3
Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.吡柔比星、依托泊苷、苯达莫司汀、利妥昔单抗（P[R]EBEN）作为挽救治疗方案用于复发/难治侵袭性非霍奇金淋巴瘤-波兰淋巴瘤研究组真实世界分析。
Pharmacol Rep. 2019 Jun;71(3):473-477. doi: 10.1016/j.pharep.2019.02.001. Epub 2019 Feb 6.
4
Treatment outcomes for older patients with relapsed/refractory aggressive lymphoma receiving salvage chemotherapy and autologous stem cell transplantation are similar to younger patients: a subgroup analysis from the phase III CCTG LY.12 trial.对于接受挽救性化疗和自体干细胞移植的复发/难治性侵袭性淋巴瘤老年患者，其治疗结果与年轻患者相似：来自 III 期 CCTG LY.12 试验的亚组分析。
Ann Oncol. 2017 Mar 1;28(3):622-627. doi: 10.1093/annonc/mdw653.
5
[Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases].GDP方案（吉西他滨、地塞米松和顺铂）治疗复发或难治性侵袭性非霍奇金淋巴瘤的疗效：附24例报告
Ai Zheng. 2008 Nov;27(11):1222-5.
6
Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.异环磷酰胺-卡铂-依托泊苷（ICE）与阿糖胞苷-顺铂-地塞米松（DHAP）作为复发或难治性淋巴瘤患者挽救性化疗的比较
Cancer Invest. 2008 May;26(4):401-6. doi: 10.1080/07357900701788098.
7
Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience.钇[90Y]替伊莫单抗替昔妥珠单抗（泽娃林）继以 BEAM（泽-贝）预处理方案和自体造血干细胞移植（ASCT）治疗复发或难治性高危 B 细胞非霍奇金淋巴瘤（NHL）：单机构意大利经验。
Ann Hematol. 2018 Sep;97(9):1619-1626. doi: 10.1007/s00277-018-3328-3. Epub 2018 Apr 16.
8
Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG).吉西他滨、地塞米松和顺铂用于复发或难治性侵袭性组织学B细胞非霍奇金淋巴瘤患者：加拿大国家癌症研究所临床试验组（NCIC-CTG）的一项II期研究
Cancer. 2004 Oct 15;101(8):1835-42. doi: 10.1002/cncr.20587.
9
Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.米托蒽醌-DHAP联合粒细胞巨噬细胞集落刺激因子：一种用于复发/难治性侵袭性非霍奇金淋巴瘤的有效但有骨髓抑制作用的挽救疗法。
Leuk Lymphoma. 1999 Nov;35(5-6):527-36. doi: 10.1080/10428199909169617.
10
Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma-outcome of rituximab-dose-intensive cyclophosphamide, etoposide, cisplatin (R-DICEP) versus R-GDP.加拿大癌症临床试验组 LY.17：一项评估复发/难治性弥漫性大 B 细胞淋巴瘤自体干细胞移植前新型挽救治疗的随机 II 期研究——利妥昔单抗剂量密集环磷酰胺、依托泊苷、顺铂（R-DICEP）与 R-GDP 的疗效比较。
Br J Haematol. 2024 Sep;205(3):881-890. doi: 10.1111/bjh.19555. Epub 2024 May 27.

引用本文的文献

1
The association of health care contact days with economic measures in the CCTG LY.12 trial.在加拿大临床试验组LY.12试验中，医疗接触天数与经济指标的关联。
Oncologist. 2025 Jun 4;30(6). doi: 10.1093/oncolo/oyaf165.
2
Contact Days Associated With Cancer Treatments in the CCTG LY.12 Trial.与 CCTG LY.12 试验中的癌症治疗相关的接触天数。
Oncologist. 2023 Sep 7;28(9):799-803. doi: 10.1093/oncolo/oyad128.

本文引用的文献

1
Indirect costs and workplace productivity loss associated with non-Hodgkin lymphoma.与非霍奇金淋巴瘤相关的间接成本和工作场所生产力损失。
Leuk Lymphoma. 2016 Nov;57(11):2636-43. doi: 10.3109/10428194.2016.1161187. Epub 2016 Apr 14.
2
Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12.吉西他滨/地塞米松/顺铂与阿糖胞苷/地塞米松/顺铂治疗复发或难治性侵袭性组织学淋巴瘤：NCIC CTG LY.12 的成本效用分析。
J Natl Cancer Inst. 2015 Apr 13;107(7). doi: 10.1093/jnci/djv106. Print 2015 Jul.
3
Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12.随机比较吉西他滨、地塞米松和顺铂与地塞米松、阿糖胞苷和顺铂化疗在自体造血干细胞移植治疗复发和难治性侵袭性淋巴瘤中的作用：NCIC-CTG LY.12.
J Clin Oncol. 2014 Nov 1;32(31):3490-6. doi: 10.1200/JCO.2013.53.9593. Epub 2014 Sep 29.
4
Absenteeism and short-term disability associated with breast cancer.与乳腺癌相关的旷工和短期残疾。
Breast Cancer Res Treat. 2011 Nov;130(1):235-42. doi: 10.1007/s10549-011-1541-z. Epub 2011 May 13.
5
Cost analysis of common treatment options for indolent follicular non-Hodgkin's lymphoma.惰性滤泡性非霍奇金淋巴瘤常见治疗方案的成本分析
Haematologica. 2005 Oct;90(10):1422-32.
6
The validity and reproducibility of a work productivity and activity impairment instrument.一种工作效率和活动能力受损评估工具的有效性和可重复性。
Pharmacoeconomics. 1993 Nov;4(5):353-65. doi: 10.2165/00019053-199304050-00006.
7
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.自体骨髓移植与挽救性化疗治疗化疗敏感型非霍奇金淋巴瘤复发的比较。
N Engl J Med. 1995 Dec 7;333(23):1540-5. doi: 10.1056/NEJM199512073332305.